CHMP recommends Mounjaro to treat type 2 diabetes
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Mounjaro, intended for the treatment of type 2 diabetes mellitus. The applicant for this medicinal product is Eli Lilly Nederland B.V.
Mounjaro will be available as a solution for injection in a pre-filled pen. The active substance of Mounjaro is tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist (ATC code: A10B). By means of its action on these receptors, tirzepatide improves glycaemic control through several different mechanisms.
The benefit of Mounjaro is its ability to improve glycaemic control in patients with type 2 diabetes. The most common side effects are hypoglycaemia when used in combination with sulphonylurea or insulin, and gastrointestinal side effects such as nausea and diarrhoea.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins